Montgomery Community Media

MedImmune, completed its acquisition of Amplimmune, a privately-held, Gaithersburg based biologics company focused on developing novel therapeutics in cancer immunology. MedImmune acquired 100% of Amplimmune’s shares for an initial consideration of $225 million and deferred consideration of up to $275 million based on reaching established development milestones. Founded in 2007 and headquartered in Gaithersburg, Amplimmune […]

AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held biologics company focused on developing novel therapeutics in cancer immunology. The buyout is designed to strengthen MedImmune’s cancer-related research, and includes an initial payment of $225 million, with the possibility of another […]